LSV Asset Management
ACAD icon

LSV Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

LSV Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Hold
17,200
– – ﹤0.01% 753
2026
Q1 		$383K Hold
17,200
– – ﹤0.01% 728
2025
Q4 		$459K Hold
17,200
– – ﹤0.01% 708
2025
Q3 		$367K Sell
17,200
-192,800
-92% -$4.56M ﹤0.01% 735
2025
Q2 		$4.53M Buy
210,000
+133,759
+175% +$2.49M 0.01% 480
2025
Q1 		$1.27M Buy
+76,241
New +$1.39M ﹤0.01% 603

Other funds holding ACAD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

LSV Asset Management's ACAD Position: Q2 2026 in Review

LSV Asset Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 17,200 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #753.

LSV Asset Management first reported a position in ACAD in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.53M in Q2 2025. 149 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • LSV Asset Management held 17,200 shares of Acadia Pharmaceuticals worth $435K as of Q2 2026.
  • LSV Asset Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of LSV Asset Management's portfolio in Q2 2026, its #753 holding.
  • LSV Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • LSV Asset Management's Acadia Pharmaceuticals position peaked at $4.53M in Q2 2025.
  • 149 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.